Literature DB >> 31925659

Association between CFH single nucleotide polymorphisms and response to photodynamic therapy in patients with central serous chorioretinopathy.

Dandan Linghu1,2,3,4, Hui Xu1,2,3,4, Zhiqiao Liang1,2,3,4, Tingting Gao1,2,3,4, Zhaojun Lin1, Xiaoxin Li1,2,3,4, Lvzhen Huang1,2,3,4, Mingwei Zhao5,6,7,8.   

Abstract

PURPOSE: To evaluate the association between single nucleotide polymorphisms (SNPs) in the complement factor H (CFH) gene and response to PDT in patients with CSC.
METHODS: 103 eyes from 93 patients with CSC were enrolled from Department of Ophthalmology of the People's Hospital Peking University. Genotyping for selected SNPs in the CFH gene was performed, and multivariate linear analysis was used to identify factors influencing PDT treatment outcomes. Genetics associations between SNPs in the CFH gene and response to PDT in patients with CSC were analyzed.
RESULTS: None of the seven SNPs examined in this study (rs800292, rs1061170, rs3753394, rs3753396, rs2284664, rs1329428, and rs1065489) showed significant associations with 1-month outcomes after PDT in patients with CSC (P > 0.05). Baseline BCVA changed at 1 month after PDT (P < 0.001), and baseline retinal thickness was associated with changes in retinal thickness at 1 month after PDT (P < 0.001). Age was significantly associated with resolution of SRF at 1 month after PDT (P = 0.004).
CONCLUSIONS: There were no significant associations between SNPs in the CFH gene and 1-month outcomes after PDT in patients with CSC. However, baseline BCVA, baseline retinal thickness, and age were significantly associated with response to PDT in patients with CSC. Larger studies with more power are necessary to further determine whether an association exists between SNPs in the CFH gene and PDT in patients with CSC.

Entities:  

Keywords:  Central serous chorioretinopathy; Complement factor H; Single nucleotide polymorphisms; Verteporfin photodynamic therapy

Mesh:

Substances:

Year:  2020        PMID: 31925659     DOI: 10.1007/s10792-019-01261-y

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  15 in total

Review 1.  Central serous chorioretinopathy: an update on pathogenesis and treatment.

Authors:  M Gemenetzi; G De Salvo; A J Lotery
Journal:  Eye (Lond)       Date:  2010-10-08       Impact factor: 3.775

2.  Gene-gene interaction of CFH, ARMS2, and ARMS2/HTRA1 on the risk of neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in Chinese population.

Authors:  L Huang; Q Meng; C Zhang; Y Sun; Y Bai; S Li; X Deng; B Wang; W Yu; M Zhao; X Li
Journal:  Eye (Lond)       Date:  2015-03-13       Impact factor: 3.775

Review 3.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

4.  PREVALENCE OF THE COMPLEMENT FACTOR H AND GSTM1 GENES POLYMORPHISMS IN PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHY.

Authors:  Marilita M Moschos; Maria Gazouli; Zisis Gatzioufas; Dimitrios Brouzas; Nikolaos Nomikarios; Sobha Sivaprasad; Panagiotis Mitropoulos; Irini P Chatziralli
Journal:  Retina       Date:  2016-02       Impact factor: 4.256

5.  Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration.

Authors:  Eiko K de Jong; Myrte B Breukink; Rosa L Schellevis; Bjorn Bakker; Jacqueline K Mohr; Sascha Fauser; Jan E E Keunen; Carel B Hoyng; Anneke I den Hollander; Camiel J F Boon
Journal:  Ophthalmology       Date:  2014-11-06       Impact factor: 12.079

6.  A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.

Authors:  Mingwei Zhao; Feng Zhang; Youxin Chen; Hong Dai; Jinfeng Qu; Chongya Dong; Xiaoping Kang; Yuling Liu; Liu Yang; Yibin Li; Peng Zhou; Chung-Ting Pan; Lijuan Zhang; Peipei Liu; Haiying Zhou; Xuan Jiao; Ying Xiong; Rong Tian; Yingyi Lu; Xiaobing Yu; Xiaoxin Li
Journal:  JAMA Ophthalmol       Date:  2015-03       Impact factor: 7.389

7.  Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy.

Authors:  Yong-Kyu Kim; Na-Kyung Ryoo; Se Joon Woo; Kyu Hyung Park
Journal:  Am J Ophthalmol       Date:  2015-04-14       Impact factor: 5.258

8.  Half-time photodynamic therapy for central serous chorioretinopathy.

Authors:  Meng-Ju Tsai; Yi-Ting Hsieh
Journal:  Optom Vis Sci       Date:  2014-09       Impact factor: 1.973

Review 9.  Central serous chorioretinopathy.

Authors:  Maria Wang; Inger Christine Munch; Pascal W Hasler; Christian Prünte; Michael Larsen
Journal:  Acta Ophthalmol       Date:  2007-07-28       Impact factor: 3.761

10.  Photodynamic therapy and central serous chorioretinopathy.

Authors:  Lina Siaudvytyte; Vaida Diliene; Goda Miniauskiene; Vilma Jurate Balciuniene
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2012
View more
  1 in total

1.  Association of central serous chorioretinopathy with single nucleotide polymorphisms in complement factor H gene in Iranian population.

Authors:  Reza Karkhaneh; Mohsen Toufighi; Akbar Amirfiroozy; Aliasghar Ahmad-Raji; Oveis Ahmadzadeh; Alborz Mahdavi; Morteza Naderan
Journal:  Eye (Lond)       Date:  2021-05-11       Impact factor: 3.775

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.